vimarsana.com
Home
Live Updates
Dr Zhang on the Background of a KEYNOTE-564 Subgroup Analysi
Dr Zhang on the Background of a KEYNOTE-564 Subgroup Analysi
Dr Zhang on the Background of a KEYNOTE-564 Subgroup Analysis in RCC
Tian Zhang, MD, MHS, discusses using the adjuvant KEYNOTE-564 regimen to treat high-risk patients with renal cell carcinoma.
Related Keywords
United States ,
American ,
,
Ut Southwestern Medical Center ,
Department Of Internal Medicine ,
Haroldc Simmons Comprehensive Cancer Center ,
American International Kidney Cancer Symposium ,
Tian Zhang ,
Internal Medicine ,
Comprehensive Cancer Center ,
Medical Center ,
Staging System ,
Genitourinary Cancer ,
Onclive Tv ,
Ut Southwestern Haroldc Simmons Comprehensive Cancer Center ,